A Phase 3, Partially Blinded, Randomized, Multi-Center, Controlled Study to Evaluate Immunogenicity, Safety and Lot to Lot Consistency of Novartis Meningococcal B Recombinant Vaccine When Administered With Routine Infant Vaccinations to Healthy Infants
Meningococcal Serogroup B Vaccine
Infections, Meningococcal
Phase 3
An extension study V12P13E1 was conducted. An analysis-ready dataset is not available for this study. There is no GSK Clinical Study Register entry for this study.
October 2015